 | Up a level |
2023
Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C. and Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol., 34 (1). S. 91 - 101. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M. and Oettle, H. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur. J. Cancer, 138. S. 172 - 182. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2014
Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R. and Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant., 49 (3). S. 410 - 416. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
2013
Hoehler, T., von Wichert, G., Schimanski, C., Kanzler, S., Moehler, M. H., Hinke, A., Seufferlein, T., Siebler, J., Hochhaus, A., Arnold, D., Hallek, M., Hofheinz, R. and Hacker, U. T. (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br. J. Cancer, 109 (6). S. 1408 - 1414. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827